JUNIPER PHARMACEUTICALS (JNP) Covered Calls

Juniper Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing therapeutics that addresses unmet medical needs in women's health. Its pipeline product includes COL-1077, a lidocaine bioadhesive gel.

You can sell covered calls on JUNIPER PHARMACEUTICALS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for JNP (prices last updated Mon 4:16 PM ET):

JUNIPER PHARMACEUTICALS (JNP) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
8.60 -0.10 8.55 8.75 35K 174 0.1B
Covered Calls For JUNIPER PHARMACEUTICALS (JNP)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jun 15 9 0.25 8.50 2.9% 40.7%
Jul 20 9 0.55 8.20 6.7% 40.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a pharmaceutical company developing therapeutics that addresses unmet medical needs in women's health. The company is leveraging its in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities to advance an internal development pipeline, while also providing valuable consultative services to its pharmaceutical industry customers. Its pipeline development is funded by cash flows from its CRINONE franchise and services business. Juniper is currently developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecological procedures. Future pipeline products will utilize Juniper's novel drug delivery technologies including its bioadhesive delivery system (BDS) and a segmented intra-vaginal ring (IVR) technology. Juniper intends to advance product candidates through Phase II proof-of-concept and will look to partner for later stage clinical trials and commercialization. The Company has developed and brought to market five bioadhesive gel products, each commercialized through alliances. These include CRINONE (progesterone gel), which is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 countries worldwide. The company was founded in December 1986 and is headquartered in Boston, MA.